RayzeBio’s Post

https://lnkd.in/g9_Mn2EU Key Insights: • Bristol Myers Squibb’s acquisition of RayzeBio brings the innovative Actinium-based radiopharmaceutical platform, along with a robust pipeline featuring multiple drug development programs, to enhance Bristol Myers Squibb’s prominent oncology portfolio Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #acquisition #HealthTrends #Insights #HealthIndustry #HealthInnovation #bristolmyerssquibb #HealthcareAnalytics #NewsUpdate #RayzeBio #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #merger #pharmainnovation #update #medicoinsights

Working in #oncology ? Check out this recent white paper from our affliate company, Magnolia Market Access, on the impact of U.S. value-based care initiatives.

Metrika’s OncoMETRIKS reports provide syndicated industry-level insights into the Canadian #oncology space. 🍁 The flagship 2023 OncoMETRIKS Oncology Corporate Leadership report is now available, serving as a tool to benchmark your pharmaceutical company versus your competitors in oncology. Find out where your company ranks today. Watch for the 2023 OncoMETRIKS Sales Force Performance reports coming later this year. #corporateleadership #cdnpharma #oncologyleaders

Comprehensive Analysis of Malignant Pleural Effusion Pipeline 2023: FDA Approvals, Treatment Strategies, and Companies – DelveInsight Report Covers LIPAC Oncology, Clover Biopharmaceuticals, Wuhan YZY #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Malignant Pleural Effusion Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | LIPAC Oncology, Clover Biopharmaceuticals, Wuhan YZY #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Research reveals that ~64% of potentially eligible patients are not benefiting from precision oncology therapies. As a solutions provider committed to improving the landscape of personalized medicine, we recognize the urgency of addressing clinical practice gaps. Visit https://lnkd.in/e3Vc2zUF to read our article which details the challenges pharmaceutical companies commonly face when integrating predictive biomarker testing into clinical care.

Visit https://lnkd.in/e3Vc2zUF to read the latest Amplity Health article which details the challenges pharmaceutical companies commonly face when integrating predictive biomarker testing into clinical care. #oncologyexpertise #biomarkerstesting #strategicleadership #solutionspartner

𝑫𝒂𝒚 𝑶𝒏𝒆 𝑩𝒊𝒐𝒑𝒉𝒂𝒓𝒎𝒂𝒄𝒆𝒖𝒕𝒊𝒄𝒂𝒍𝒔 𝑽𝒆𝒏𝒕𝒖𝒓𝒆𝒔 𝒊𝒏𝒕𝒐 𝑨𝑫𝑪𝒔 𝒘𝒊𝒕𝒉 $55𝑴 𝑳𝒊𝒄𝒆𝒏𝒔𝒊𝒏𝒈 𝑫𝒆𝒂𝒍 𝑭𝒐𝒍𝒍𝒐𝒘𝒊𝒏𝒈 𝑭𝑫𝑨 𝑨𝒑𝒑𝒓𝒐𝒗𝒂𝒍 𝒂𝒏𝒅 $108𝑴 𝑩𝒐𝒐𝒔𝒕 💉🔬 Fresh off their first FDA approval and a $108M boost from a priority review voucher sale, Day One Biopharmaceuticals is diving into the hottest area in oncology: antibody-drug conjugates (ADCs) 🧬. The company announced a $55M upfront licensing deal with MabCare Therapeutics for ADC MTX-13, which is set to enter Phase 1 soon. Day One is proud to join the wave of biotechs advancing ADCs, an area that has captivated both small and large pharma. 💉🔬 Day One Biopharmaceuticals is taking applications to join their Commercial Community in Commercial, Portfolio Planning, Market Access, Sales or Marketing. (Remote) https://lnkd.in/edJpx7gv #Biopharma #Oncology #Innovation #ADCs #DayOneBiopharma #MabCareTherapeutics #CancerResearch

ROI Test (residue on ignition) for Gefitinib sample (Raw Material). Gefitinib: Pharmaceutical product used as anti-tumor (lung cancer). #ROI #roi #gefitinib #lung_cancer #cancer #pharmaceuticals

Research reveals that ~64% of potentially eligible patients are not benefiting from precision oncology therapies. As a solutions provider committed to improving the landscape of personalized medicine, we recognize the urgency of addressing clinical practice gaps. Our newest article details the challenges pharmaceutical companies commonly face when integrating predictive biomarker testing into clinical care. Read the article written by Ken Ruppel, our VP of Precision Medicine, here: https://lnkd.in/e3Vc2zUF